Cargando…
A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies
BACKGROUND: The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020025/ https://www.ncbi.nlm.nih.gov/pubmed/35443657 http://dx.doi.org/10.1186/s12890-022-01922-2 |
_version_ | 1784689436621012992 |
---|---|
author | Wong, Alyson W. Koo, John Ryerson, Christopher J. Sadatsafavi, Mohsen Chen, Wenjia |
author_facet | Wong, Alyson W. Koo, John Ryerson, Christopher J. Sadatsafavi, Mohsen Chen, Wenjia |
author_sort | Wong, Alyson W. |
collection | PubMed |
description | BACKGROUND: The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally. METHODS: We conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of Science databases between 2000 and 2020. We compared ILD costs between countries according to the share of costs towards each country’s respective gross domestic product (GDP) per capita. Costs are reported in 2020 USD. RESULTS: We identified 25 disease cost studies and 7 CEAs. The direct medical costs ranged between $1824 and $116,927 annually per patient (median $32,834; 14–180% of GDP per capita in Western countries). The leading drivers of direct costs were inpatient (55%), outpatient (22%), and medication costs (18%), based on pooled estimates. Annual indirect costs ranged from $7149 to $10,902 per employed patient (median $9607; 12–23% of GDP per capita). Among the 7 CEAs, only 1 study (14%) showed an ILD therapy (ambulatory oxygen) was cost-effective compared to best supportive care. CONCLUSION: The direct and indirect costs associated with ILD are consistently high in all countries with available data, with cost-effectiveness profiles of new therapies generally undesirable. Globally, the median total direct cost for ILD equates to 51% of a country’s GDP per capita and has been increasing over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-01922-2. |
format | Online Article Text |
id | pubmed-9020025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90200252022-04-21 A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies Wong, Alyson W. Koo, John Ryerson, Christopher J. Sadatsafavi, Mohsen Chen, Wenjia BMC Pulm Med Research BACKGROUND: The economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally. METHODS: We conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of Science databases between 2000 and 2020. We compared ILD costs between countries according to the share of costs towards each country’s respective gross domestic product (GDP) per capita. Costs are reported in 2020 USD. RESULTS: We identified 25 disease cost studies and 7 CEAs. The direct medical costs ranged between $1824 and $116,927 annually per patient (median $32,834; 14–180% of GDP per capita in Western countries). The leading drivers of direct costs were inpatient (55%), outpatient (22%), and medication costs (18%), based on pooled estimates. Annual indirect costs ranged from $7149 to $10,902 per employed patient (median $9607; 12–23% of GDP per capita). Among the 7 CEAs, only 1 study (14%) showed an ILD therapy (ambulatory oxygen) was cost-effective compared to best supportive care. CONCLUSION: The direct and indirect costs associated with ILD are consistently high in all countries with available data, with cost-effectiveness profiles of new therapies generally undesirable. Globally, the median total direct cost for ILD equates to 51% of a country’s GDP per capita and has been increasing over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-01922-2. BioMed Central 2022-04-20 /pmc/articles/PMC9020025/ /pubmed/35443657 http://dx.doi.org/10.1186/s12890-022-01922-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wong, Alyson W. Koo, John Ryerson, Christopher J. Sadatsafavi, Mohsen Chen, Wenjia A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title | A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title_full | A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title_fullStr | A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title_full_unstemmed | A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title_short | A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
title_sort | systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020025/ https://www.ncbi.nlm.nih.gov/pubmed/35443657 http://dx.doi.org/10.1186/s12890-022-01922-2 |
work_keys_str_mv | AT wongalysonw asystematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT koojohn asystematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT ryersonchristopherj asystematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT sadatsafavimohsen asystematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT chenwenjia asystematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT wongalysonw systematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT koojohn systematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT ryersonchristopherj systematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT sadatsafavimohsen systematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies AT chenwenjia systematicreviewontheeconomicburdenofinterstitiallungdiseaseandthecosteffectivenessofcurrenttherapies |